Search

Your search keyword '"Cedrés S"' showing total 106 results
Start Over Author "Cedrés S"
106 results on '"Cedrés S"'

23. 572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials

Author

Santa Gadea, O. Saavedra, Hernando-Calvo, A., Berché, R., Matos, I., Gardeazabal, I., Pedrazzoli, A.B. Azaro, Villar, M. Vieito, Braña, I., Casal, G. Alonso, Galvao de Aguiar, V., Pedrola, A., Martinez, G. Argiles, Mercadé, T. Macarulla, Capdevila, J., Cedres, S., Oaknin, A., Elez, E., Tabernero, J., Dienstmann, R., and Garralda, E.

Published
2020
Full Text
View/download PDF

34. Rectal Metastases from Squamous Cell Carcinoma: A Case Report and Review of the Literature

Author

Cedrés, S., Mulet-Margalef, N., Montero, M. A., Martinez, P., Martínez, A., and Felip, E.

Subjects
Article Subject, respiratory system, respiratory tract diseases
Abstract

Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer. The most frequent sites of distant metastasis are the liver, adrenal glands, bones and brain. Gastrointestinal metastases are uncommon and rectal metastases are extremely rare. Here we report a case of squamous cell carcinoma of the lung with rectal metastases.

Published
2012
Full Text
View/download PDF

42. Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Author

Cedrés, S., Ponce-Aix, S., Pardo-Aranda, N., Navarro-Mendivil, A., Martinez-Marti, A., Zugazagoitia, J., Sansano, I., Montoro, M.A., Enguita, A., and Felip, E.

Subjects
*MESOTHELIOMA, *PROGRAMMED cell death 1 receptors, *PROTEIN kinase B, *PTEN protein, *PROTEIN expression, *IMMUNOSTAINING, *PROGNOSIS
Abstract

Background Malignant pleural mesothelioma (MPM) frequently express elevated AKT/mTOR activity. Previous reports in gliomas, colon, breast and prostate cancer suggest that PTEN/PI3 K pathway may be important for the induction of PD-L1 expression. This study explored the expression of PTEN/PI3 K pathway and PD-L1 in MPM and its relationship with the patient́s prognosis Material and methods Twenty seven consecutive MPM patients were reviewed. Formalin-fixed, paraffin-embedded tissue biopsies were used for immunohistochemical analysis of PTEN/PI3 K pathway and PD-L1 Results Expression of PTEN, mTOR, pAKT, p4EBP1, peif4E, pS6 and FOXO3a was found in 88.5%, 92.3%, 78.3%, 38.5%, 100%, 52.2% and 100% of tumors and PD-L1 in 23%. We found a significant correlation between pAKT, FOXO3a and PD-L1 expression and longer overall survival (p < 0.05). We did not identify significant association between the level of PD-L1 expression and alterations in PI3 K pathway Conclusions This study shows PTEN/PI3 K pathway and PD-L1 in MPM are frequently activated. Our results suggests that there is not association between PD-L1 and the involvement of the PI3 K pathway in MPM. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

49. Dynamic changes in circulating tumor <scp>DNA</scp> assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in <scp>NSCLC</scp>

Author

Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez‐Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo‐Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip, Institut Català de la Salut, [Carbonell C, Frigola J, Lenza L, Soleda M, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pardo N, Callejo A, Iranzo P, Valdivia A, Cedrés S, Martinez-Marti A, Navarro A] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Priano I] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gonzalo-Ruiz J] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Vivancos A] Cancer Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Felip E] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Cancer Research, Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::Cell-Free Nucleic Acids::Circulating Tumor DNA [CHEMICALS AND DRUGS], Marcadors tumorals, Medicaments antineoplàstics - Ús terapèutic, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], General Medicine, Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES], neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], nucleótidos y nucleósidos de ácidos nucleicos::ácidos nucleicos::ácidos nucleicos libres de células::ADN tumoral circulante [COMPUESTOS QUÍMICOS Y DROGAS], Oncology, Genetics, Molecular Medicine, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], Pulmons - Càncer - Tractament
Abstract

Immune checkpoint inhibitors; Liquid biopsy Inhibidores del punto de control inmunitario; Biopsia líquida Inhibidors del punt de control immunitari; Biòpsia líquida Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients benefit from this type of treatment. Here, we assessed the value of shallow whole-genome sequencing (sWGS) on plasma samples to monitor ICI benefit. We applied sWGS on cell-free DNA (cfDNA) extracted from plasma samples of 45 patients with metastatic NSCLC treated with ICIs. Over 150 samples were obtained before ICI treatment initiation and at several time points throughout treatment. From sWGS data, we computed the tumor fraction (TFx) and somatic copy number alteration (SCNA) burden and associated them with ICI benefit and clinical features. TFx at baseline correlated with metastatic lesions at the bone and the liver, and high TFx (≥ 10%) associated with ICI benefit. Moreover, its assessment in on-treatment samples was able to better predict clinical efficacy, regardless of the TFx levels at baseline. Finally, for a subset of patients for whom SCNA burden could be computed, increased burden correlated with diminished benefit following ICI treatment. Thus, our data indicate that the analysis of cfDNA by sWGS enables the monitoring of two potential biomarkers—TFx and SCNA burden—of ICI benefit in a cost-effective manner, facilitating multiple serial-sample analyses. Larger cohorts will be needed to establish its clinical potential. This work was partially supported by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945; Grant for Oncology Innovation to the Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain); the Insituto de Salud Carlos III through the projects PI20/00987 to EF and PI22/01585 to RA (Co-funded by European Union). The healthcare business of Merck KGaA, Darmstadt, Germany reviewed the manuscript for medical accuracy only before journal submission.

Published
2023

50. Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients

Author

Joan Frigola, Caterina Carbonell, Enriqueta Felip, Alejandro Navarro, P. Iranzo, Alex Martinez-Marti, A. Callejo, Nely Diaz, D. Marmolejo, Ramon Amat, Susana Cedres, J.D. Assaf, N. Pardo, Institut Català de la Salut, [Callejo A, Iranzo P, Diaz N, Assaf JD, Cedrés S, Martinez-Marti A, Navarro A, Pardo N] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Frigola J, Carbonell C, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Marmolejo D] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Felip E] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Multivariate analysis, LDH, medicine.medical_treatment, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], ECOG Performance Status, Other subheadings::Other subheadings::/drug therapy [Other subheadings], NSCLC, Article, immune checkpoint inhibitors, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Other subheadings::/therapeutic use [Other subheadings], Adverse effect, Survival analysis, RC254-282, Medicaments antineoplàstics - Ús terapèutic - Eficàcia, Otros calificadores::/uso terapéutico [Otros calificadores], business.industry, Hazard ratio, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, biomarkers, Retrospective cohort study, Immunotherapy, Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES], neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], immune related adverse events, 030104 developmental biology, 030220 oncology & carcinogenesis, Cohort, immunotherapy, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], business, Pulmons - Càncer - Tractament
Abstract

Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment. Unfortunately, only some patients benefit from these therapies. Thus, certain clinicopathological characteristics of the patients have been proposed as biomarkers of ICIs response. We assembled a retrospective cohort of 262 NSCLC patients treated with ICIs, compiled relevant clinicopathological characteristics, and studied their associations with treatment outcome using Cox proportional-hazards survival models. Additionally, we investigated the interrelations between clinicopathological features and devised a method to create a compendium associated with ICIs response by selecting those that provide non-redundant information. In multivariate analyses, ECOG performance status (hazard ratio (HR) 1.37 (95% CI 1.11 to 1.68), p &lt, 0.005), LDH (HR 1.24 (95% CI 1.03 to 1.48), p = 0.02)) and PD-L1 negativity were associated with decreased PFS (HR 1.92 (95% CI 1.03 to 3.58), p &lt, 0.04), whereas presentation of immune-related adverse events (irAEs) (HR 0.35 (95% CI 0.22 to 0.55, p &lt, 0.005) or females (HR 0.52 (95% CI 0.33 to 0.80, p &lt, 0.005) had longer progression-free survival. Additionally, numerous clinicopathological indicators were found to be interrelated. Thus, we searched for features that provide non-redundant information, and found the combination of LDH levels, irAEs, and gender to have a better association with ICIs treatment response (cross-validated c-index = 0.66). We concluded that several clinicopathological features showed prognostic value in our real-world cohort. However, some are interrelated, and compendiums of features should therefore consider these interactions. Joint assessment of LDH, irAEs, and gender may be a good prognostic compendium.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results